HLS Therapeutics Inc. updated consolidated revenue guidance for the full year 2024. for the year, the company is lowering its full year consolidated revenue guidance to a range of $60 million - $62 million from $63.5 million -$66.5 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.65 CAD | +3.11% |
|
+8.63% | -7.59% |
Jul. 02 | National Bank on DRI Healthcare Trust's Xenpozyme Royalty Stream Acquisition | MT |
Jul. 02 | HLS Therapeutics Sells Xenpozyme Royalty Interest to DRI Healthcare Trust | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.59% | 85.14M | |
+26.00% | 75.67B | |
+11.84% | 8.62B | |
+1.22% | 8.29B | |
-36.37% | 6.6B | |
+19.60% | 5.45B | |
+2.20% | 4.1B | |
-9.97% | 3.76B | |
-11.12% | 3.3B | |
+9.19% | 3.22B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024